Zevalin Completes Transition To ASP-Based Reimbursement In OPPS
Executive Summary
Spectrum Pharmaceuticals' radiopharmaceutical Zevalin (ibritumomab tiuxetan) will be reimbursed like other Medicare Part B drugs administered in the hospital outpatient setting, according to the final outpatient prospective payment update for 2010
You may also be interested in...
Cancer Drug Zevalin May Finally Thrive Under Spectrum
The small oncology company may be able to succeed with the non-Hodgkin lymphoma drug where others have failed.
Cancer Drug Zevalin May Finally Thrive Under Spectrum
The small oncology company may be able to succeed with the non-Hodgkin lymphoma drug where others have failed.
CMS Proposes Compendia Publish All Materials Related To Listing Decision
In an effort to increase the transparency in the compendia listing process, CMS is proposing that approved compendia publish all materials used in evaluating an off-label usage of a drug